Recent Finacing
Recent Raise
Pieris AG develops Anticalins—engineered ~20 kDa human lipocalin‑derived binding proteins—and advances PRS‑050 (anti‑VEGF) and PRS‑110 (c‑Met) through preclinical and early clinical development with pharma collaborations.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
